Pub Date : 2024-02-28DOI: 10.31928/2664-4479-2024.1.7178
O. Torbas, S. O. Progonov, Y. Sirenko, G. D. Radchenko
For a long time, the problem of the formation of diastolic dysfunction (DD) of the left ventricle (LV) in patients with arterial hypertension (AH) remained insufficiently studied. It was demonstrated that the formation of LV DD is largely related to the increase in stiffness of this heart chamber. We decided to evaluate the extent to which increased LV stiffness, determined noninvasively by echocardiography, is associated with LV diastolic dysfunction and determine the relationship of this method with arterial stiffness indicators for which validated methods have been developed.Materials and methods. A one-center registry called PULSE-COR was established in 2011 and is still in operation. There were 779 AH participants in our sample. A distinct cohort of patients (n=283) with essential AH and no substantial comorbidities were found from the final analysis, which comprised 320 patients who had undergone all requisite diagnostic procedures. Our tool of choice for measuring carotid-femoral pulse wave velocity (cfPWV) was the SphygmoCor device (AtCor, Australia). We also used the VaSera 1500 device (Fukuda Denshi, Japan) to measure cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI). Vascular ultrasound and intima-media thickness measurement (IMT) were included in the ultrasound diagnosis. The ASE 2016 recommendations were followed for the evaluation of diastolic LV function, and the standardized ASE protocol was followed for echocardiography. A standardized formula was used to assess the ventriculo-arterial coupling (VAC) which also included LV end-systolic elastance (Ees) and arterial elastance (Ea) evaluation. We conducted Spearman correlation analysis to identify relationships.Results and discussion. Our cohort were patients with AH, 51 % males; the mean age was 53.6±2.0 years. Mean office blood pressure (BP) was 159.8±4.5 mm Hg for systolic (SBP), 97.9±2.6 mm Hg for diastolic (DBP), 62.0±3.5 mm Hg for pulse blood (PBP) BP, and 76.6±2.2 bits per minute was the mean heart rate (HR). Both the left and right CAVI (R=0.698; p=0.012 and R=0.683; p=0.014) showed a strong correlation with VAC. Both E/A and E/e showed a substantial correlation with ABI (R=0.716; p=0.006 and R=0.764; p=0.002, respectively). cfPWV was linked with nearly the same parameters (R=0.248; p=0.001 for correlation with IMT, R=0.382; p=0.01 for correlation with low-density lipoproteins). Ea was substantially associated with IMT (R=0.491; p=0.24), total cholesterol (R=0.499; p=0.07), and low-density lipoproteins (R=0.687; p=0.001). Ees was substantially correlated with end diastolic volume (R=0.644; p=0.001), blood lymphocytes (R=–0.678; p=0.001), E/A (R=0.159; p=0.007), and E/e’ (R=–0.130; p=0.029).Conclusions. We have found a substantial correlation between validated arterial stiffness measurements and non-invasive LV stiffness evaluation parameters (VAC). VAC also was associated with LV diastolic function parameters
长期以来,人们对动脉高血压(AH)患者左心室舒张功能障碍(DD)的形成问题研究不足。研究表明,左心室舒张功能障碍的形成在很大程度上与左心室僵硬度的增加有关。我们决定评估通过超声心动图无创测定的左心室僵硬度增加在多大程度上与左心室舒张功能障碍有关,并确定该方法与动脉僵硬度指标的关系,目前已开发出有效的方法。一个名为 PULSE-COR 的单中心注册中心成立于 2011 年,目前仍在运行。我们的样本中有 779 名 AH 参与者。在最终分析中,我们发现了一个独特的患者群(人数为 283 人),他们都是基本 AH 患者,没有严重的合并症,其中包括 320 名接受过所有必要诊断程序的患者。我们选择的颈动脉-股动脉脉搏波速度(cfPWV)测量工具是 SphygmoCor 设备(澳大利亚 AtCor 公司)。我们还使用 VaSera 1500 设备(日本 Fukuda Denshi)测量心-踝血管指数(CAVI)和踝-肱指数(ABI)。血管超声和血管内中膜厚度测量(IMT)包括在超声诊断中。舒张左心室功能评估遵循 ASE 2016 建议,超声心动图检查遵循 ASE 标准化方案。采用标准化公式评估心室-动脉耦合(VAC),其中还包括左心室收缩末期弹性(Ees)和动脉弹性(Ea)评估。我们进行了斯皮尔曼相关分析,以确定两者之间的关系。我们的研究对象为 AH 患者,51% 为男性;平均年龄为(53.6±2.0)岁。平均办公室血压(BP)为收缩压(SBP)(159.8±4.5 mm Hg),舒张压(DBP)(97.9±2.6 mm Hg),脉搏血压(PBP)(62.0±3.5 mm Hg),平均心率(HR)(76.6±2.2 bits per minute)。左侧和右侧 CAVI(R=0.698;p=0.012 和 R=0.683;p=0.014)均与 VAC 密切相关。E/A和E/e与ABI都有很大的相关性(分别为R=0.716;p=0.006和R=0.764;p=0.002)。cfPWV与几乎相同的参数有关(与IMT的相关性为R=0.248;p=0.001,与低密度脂蛋白的相关性为R=0.382;p=0.01)。Ea与IMT(R=0.491;p=0.24)、总胆固醇(R=0.499;p=0.07)和低密度脂蛋白(R=0.687;p=0.001)密切相关。Ees与舒张末期容积(R=0.644;p=0.001)、血淋巴细胞(R=-0.678;p=0.001)、E/A(R=0.159;p=0.007)和E/e'(R=-0.130;p=0.029)有很大的相关性。我们发现,经过验证的动脉僵化测量值与非侵入性左心室僵化评估参数(VAC)之间存在很大的相关性。VAC 还与左心室舒张功能参数相关
{"title":"Реєстр PULSE-COR: взаємозв’язок між еластичністю лівого шлуночка та жорсткістю артерій у пацієнтів з есенціальною артеріальною гіпертензією","authors":"O. Torbas, S. O. Progonov, Y. Sirenko, G. D. Radchenko","doi":"10.31928/2664-4479-2024.1.7178","DOIUrl":"https://doi.org/10.31928/2664-4479-2024.1.7178","url":null,"abstract":"For a long time, the problem of the formation of diastolic dysfunction (DD) of the left ventricle (LV) in patients with arterial hypertension (AH) remained insufficiently studied. It was demonstrated that the formation of LV DD is largely related to the increase in stiffness of this heart chamber. We decided to evaluate the extent to which increased LV stiffness, determined noninvasively by echocardiography, is associated with LV diastolic dysfunction and determine the relationship of this method with arterial stiffness indicators for which validated methods have been developed.Materials and methods. A one-center registry called PULSE-COR was established in 2011 and is still in operation. There were 779 AH participants in our sample. A distinct cohort of patients (n=283) with essential AH and no substantial comorbidities were found from the final analysis, which comprised 320 patients who had undergone all requisite diagnostic procedures. Our tool of choice for measuring carotid-femoral pulse wave velocity (cfPWV) was the SphygmoCor device (AtCor, Australia). We also used the VaSera 1500 device (Fukuda Denshi, Japan) to measure cardio-ankle vascular index (CAVI) and ankle-brachial index (ABI). Vascular ultrasound and intima-media thickness measurement (IMT) were included in the ultrasound diagnosis. The ASE 2016 recommendations were followed for the evaluation of diastolic LV function, and the standardized ASE protocol was followed for echocardiography. A standardized formula was used to assess the ventriculo-arterial coupling (VAC) which also included LV end-systolic elastance (Ees) and arterial elastance (Ea) evaluation. We conducted Spearman correlation analysis to identify relationships.Results and discussion. Our cohort were patients with AH, 51 % males; the mean age was 53.6±2.0 years. Mean office blood pressure (BP) was 159.8±4.5 mm Hg for systolic (SBP), 97.9±2.6 mm Hg for diastolic (DBP), 62.0±3.5 mm Hg for pulse blood (PBP) BP, and 76.6±2.2 bits per minute was the mean heart rate (HR). Both the left and right CAVI (R=0.698; p=0.012 and R=0.683; p=0.014) showed a strong correlation with VAC. Both E/A and E/e showed a substantial correlation with ABI (R=0.716; p=0.006 and R=0.764; p=0.002, respectively). cfPWV was linked with nearly the same parameters (R=0.248; p=0.001 for correlation with IMT, R=0.382; p=0.01 for correlation with low-density lipoproteins). Ea was substantially associated with IMT (R=0.491; p=0.24), total cholesterol (R=0.499; p=0.07), and low-density lipoproteins (R=0.687; p=0.001). Ees was substantially correlated with end diastolic volume (R=0.644; p=0.001), blood lymphocytes (R=–0.678; p=0.001), E/A (R=0.159; p=0.007), and E/e’ (R=–0.130; p=0.029).Conclusions. We have found a substantial correlation between validated arterial stiffness measurements and non-invasive LV stiffness evaluation parameters (VAC). VAC also was associated with LV diastolic function parameters","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140420919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-28DOI: 10.31928/2664-4479-2024.1.103112
F. Hladkykh
Myocarditis is a group of inflammatory diseases of the heart muscle against the background of the absence of acute or chronic ischemic heart disease, which are diagnosed according to established histological, immunological and immunohistochemical criteria.Objective. Summarize current information on the immunopathogenesis of myocarditis based on data from open sources of information.Methods. Publications were selected based on PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection and Google Scholar databases, which covered information on the immunopathogenesis of myocarditis.Results. Viral infections are the most common cause of myocarditis, along with some bacteria and protozoa. Chronic immune stimulation or autoimmunity in chronic viral myocarditis results from incomplete resolution of the viral infection or response to a previous virus or immune-mediated chronic tissue injury. An active autoimmune response in human myocarditis, both at the cellular and humoral levels, is the immunological basis for the development of this pathology. Myocarditis caused by COVID-19 is a new entity. At the moment, four main manifestations of myocarditis in the context of SARS-CoV-2 have been identified: myocarditis associated with an acute infection of COVID-19, post-acute syndrome of COVID-19 (or prolonged syndrome of COVID-19), multisystem inflammatory syndrome, and myocarditis due to related to vaccination. Autoimmune reactions probably contribute to molecular mimicry – they activate virus-specific T-cells that attack the myocardium. During this phase, high concentrations of cytokines (eg, tumor necrosis factor, interleukins 1a, 1b, 2, and interferon-γ) are produced. These cytokines, together with antibodies against viral and cardiac proteins, further exacerbate cardiac damage and systolic dysfunction due to contractile dysfunction and matrix proteins.Conclusions. CD4+T-cells are defined as the main driving forces of heart-specific autoimmunity in myocarditis. Dysregulated CD4+ T-cell populations and their associated cytokines are critical for the development and progression of myocarditis and may serve as therapeutic targets and the development of new treatment approaches.
心肌炎是在没有急性或慢性缺血性心脏病的背景下发生的一组心肌炎性疾病,根据既定的组织学、免疫学和免疫组化标准进行诊断。根据公开信息来源的数据,总结当前有关心肌炎免疫发病机制的信息。根据PubMed、Clinical Key Elsevier、Cochrane Library、eBook Business Collection和Google Scholar数据库中涉及心肌炎免疫发病机制信息的文献进行筛选。病毒感染是心肌炎最常见的病因,此外还有一些细菌和原生动物。慢性病毒性心肌炎中的慢性免疫刺激或自身免疫是由于病毒感染未完全清除或对先前病毒的反应或免疫介导的慢性组织损伤所致。人类心肌炎在细胞和体液水平上的活跃自身免疫反应是这种病变发生的免疫学基础。由 COVID-19 引起的心肌炎是一种新的疾病。目前,SARS-CoV-2 导致的心肌炎主要有四种表现形式:与 COVID-19 急性感染相关的心肌炎、COVID-19 急性后综合征(或 COVID-19 延长综合征)、多系统炎症综合征以及与疫苗接种相关的心肌炎。自身免疫反应可能有助于分子模拟--它们激活了攻击心肌的病毒特异性 T 细胞。在这一阶段,会产生高浓度的细胞因子(如肿瘤坏死因子、白细胞介素 1a、1b、2 和干扰素-γ)。这些细胞因子与针对病毒和心脏蛋白的抗体一起,进一步加剧了由于收缩功能障碍和基质蛋白导致的心脏损伤和收缩功能障碍。CD4+T细胞被定义为心肌炎中心脏特异性自身免疫的主要驱动力。失调的 CD4+ T 细胞群及其相关细胞因子对心肌炎的发生和发展至关重要,可作为治疗靶点并开发新的治疗方法。
{"title":"Імунопатологічні аспекти етіопатогенезу міокардиту","authors":"F. Hladkykh","doi":"10.31928/2664-4479-2024.1.103112","DOIUrl":"https://doi.org/10.31928/2664-4479-2024.1.103112","url":null,"abstract":"Myocarditis is a group of inflammatory diseases of the heart muscle against the background of the absence of acute or chronic ischemic heart disease, which are diagnosed according to established histological, immunological and immunohistochemical criteria.Objective. Summarize current information on the immunopathogenesis of myocarditis based on data from open sources of information.Methods. Publications were selected based on PubMed, Clinical Key Elsevier, Cochrane Library, eBook Business Collection and Google Scholar databases, which covered information on the immunopathogenesis of myocarditis.Results. Viral infections are the most common cause of myocarditis, along with some bacteria and protozoa. Chronic immune stimulation or autoimmunity in chronic viral myocarditis results from incomplete resolution of the viral infection or response to a previous virus or immune-mediated chronic tissue injury. An active autoimmune response in human myocarditis, both at the cellular and humoral levels, is the immunological basis for the development of this pathology. Myocarditis caused by COVID-19 is a new entity. At the moment, four main manifestations of myocarditis in the context of SARS-CoV-2 have been identified: myocarditis associated with an acute infection of COVID-19, post-acute syndrome of COVID-19 (or prolonged syndrome of COVID-19), multisystem inflammatory syndrome, and myocarditis due to related to vaccination. Autoimmune reactions probably contribute to molecular mimicry – they activate virus-specific T-cells that attack the myocardium. During this phase, high concentrations of cytokines (eg, tumor necrosis factor, interleukins 1a, 1b, 2, and interferon-γ) are produced. These cytokines, together with antibodies against viral and cardiac proteins, further exacerbate cardiac damage and systolic dysfunction due to contractile dysfunction and matrix proteins.Conclusions. CD4+T-cells are defined as the main driving forces of heart-specific autoimmunity in myocarditis. Dysregulated CD4+ T-cell populations and their associated cytokines are critical for the development and progression of myocarditis and may serve as therapeutic targets and the development of new treatment approaches.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"117 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140421166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-28DOI: 10.31928/2664-4479-2024.1.5970
O. Honchar
The aim – to study the influence of hypertension (HT) on the dynamics of natural recovery of physical functional status in the early period after hospitalization for COVID-19 and to develop a model for predicting recovery results at 1 month after discharge.Materials and methods. 221 hospitalized patients with COVID-19 (age 53.4±13.6 years, 53 % women) were included in the study, 176 of whom underwent the 6-minute walk test (6MWT) using an extended protocol within 1-2 days before discharge. A repeat visit to assess the dynamics of natural recovery was performed at 1 month after discharge.Results and discussion. Pre-discharge 6-minute walk distance was 378±57 m in patients with HT and 418±75 m without it, p=0.001, during the second visit – 440±52 versus 478±68, p=0.002; the achieved percentage of the individually predicted distance was 67.4±10.5 vs. 69.5±13.6 % and 81.6±9.9 vs. 81.9±15.7 %, respectively, p>0.05 for both visits. The increase in heart rate during the test at visit 1 was 18.5±8.3 versus 30.1±19.3 bpm, p<0.001, the percentage of chronotropic reserve utilizatoin was 21.3±9.6 % versus 29.2±11.4 %, p<0.001. During the second visit, residual manifestations of this trend were observed, with an increase in HR by 24.0±9.5 vs. 30.8±12.1, p=0.003 and the use of chronotropic reserve of 28.1±10.1 % vs. 33.4±12.4 %, respectively, p=0.029. The developed multivariate linear regression model explained 59 % of the variability in the achieved percentage of the individually predicted 6-minute walk distance at 1 month after discharge. The use of machine learning allowed to create an artificial neural network based regression model that used age, height, use of remdesivir in treatment, and SBP and DBP values at the time of discharge as predictors, and explained 90 % of observed variability.Conclusions. Hospitalized patients with COVID-19 were characterized by a decrease in the general physical functional status as assessed by 6MWT at the time of discharge and incomplete recovery after 1 month. Presence of hypertension was associated with more pronounced disturbances of the autonomic regulation of heart rate, but did not affect the reached percentage of the distance walked. The proposed artificial neural network based regression model allows for a high accuracy prediction of the 6MWT results at 1 month after discharge, which can be used in the selection of candidates for cardiopulmonary rehabilitation programs.
{"title":"Physical functional recovery in the early period after hospitalization for COVID-19: impact of hypertension and outcome prediction model","authors":"O. Honchar","doi":"10.31928/2664-4479-2024.1.5970","DOIUrl":"https://doi.org/10.31928/2664-4479-2024.1.5970","url":null,"abstract":"The aim – to study the influence of hypertension (HT) on the dynamics of natural recovery of physical functional status in the early period after hospitalization for COVID-19 and to develop a model for predicting recovery results at 1 month after discharge.Materials and methods. 221 hospitalized patients with COVID-19 (age 53.4±13.6 years, 53 % women) were included in the study, 176 of whom underwent the 6-minute walk test (6MWT) using an extended protocol within 1-2 days before discharge. A repeat visit to assess the dynamics of natural recovery was performed at 1 month after discharge.Results and discussion. Pre-discharge 6-minute walk distance was 378±57 m in patients with HT and 418±75 m without it, p=0.001, during the second visit – 440±52 versus 478±68, p=0.002; the achieved percentage of the individually predicted distance was 67.4±10.5 vs. 69.5±13.6 % and 81.6±9.9 vs. 81.9±15.7 %, respectively, p>0.05 for both visits. The increase in heart rate during the test at visit 1 was 18.5±8.3 versus 30.1±19.3 bpm, p<0.001, the percentage of chronotropic reserve utilizatoin was 21.3±9.6 % versus 29.2±11.4 %, p<0.001. During the second visit, residual manifestations of this trend were observed, with an increase in HR by 24.0±9.5 vs. 30.8±12.1, p=0.003 and the use of chronotropic reserve of 28.1±10.1 % vs. 33.4±12.4 %, respectively, p=0.029. The developed multivariate linear regression model explained 59 % of the variability in the achieved percentage of the individually predicted 6-minute walk distance at 1 month after discharge. The use of machine learning allowed to create an artificial neural network based regression model that used age, height, use of remdesivir in treatment, and SBP and DBP values at the time of discharge as predictors, and explained 90 % of observed variability.Conclusions. Hospitalized patients with COVID-19 were characterized by a decrease in the general physical functional status as assessed by 6MWT at the time of discharge and incomplete recovery after 1 month. Presence of hypertension was associated with more pronounced disturbances of the autonomic regulation of heart rate, but did not affect the reached percentage of the distance walked. The proposed artificial neural network based regression model allows for a high accuracy prediction of the 6MWT results at 1 month after discharge, which can be used in the selection of candidates for cardiopulmonary rehabilitation programs.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"53 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140422032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.4047
O. Torbas, Y. Sirenko, S. Progonov
The aim – to assess the influence of various external factors and stress due to a large-scale military invasion on the daily blood pressure (BP) profile.Materials and methods. This was a retrospective analysis of examined patients who underwent ABPM in the last 5 years. We conditionally divided the observation period into several time intervals: the «War» – 1st group, the «Before the war» – 2nd group, the «Covid» – 3rd group, and the «Peace» – 4th group, in each of it 20 patients were selected by the method of random numbers. All patients underwent ABPM using the Watch BP 03 device (Microlife AG, Switzerland).Results. All groups were comparable according to the age, gender, and average daily BP and heart rate parameters of participants. Patients of all groups were middle-aged, the amount of men and women was equal in all groups, groups were comparable according to the results of average daily systolic (SBP), diastolic (DBP), pulse (PBP) BP and heart rate. We found that the 1st group had a significantly lower percentage of SBP and DBP decrease at night compared to all other groups (7.6±1.3% for SBP and 10.2±1.4% for DBP). The standard deviation of SBP and DBP was significantly higher in the 2nd group (19.8±1.1 and 14.2±0.7, respectively) compared to the 1st group (16.0±0.9 and 11.7±0.6, respectively) and 3rd (16.2±0.7 and 11.8±0.7, respectively). The highest frequency of non-dippers for SBP and DBP was observed in the 1st group (60 and 45 % respectively).Conclusions. During the war, the reduction of SBP and DBP at night in patients with hypertension was significantly lower than in the period before the war, pandemic Covid-19, and peace pre-war. There was also a higher number of non-dippers in this group.
目的是评估由于大规模军事入侵导致的各种外部因素和压力对日常血压(BP)的影响。材料和方法。这是对过去5年中接受ABPM检查的患者的回顾性分析。我们有条件地将观察期分为几个时间间隔:“战争”-第一组,“战争前”-第二组,“新冠”-第三组,“和平”-第四组,每组采用随机数法选择20例患者。所有患者均使用Watch BP 03装置(Microlife AG,瑞士)进行ABPM。根据参与者的年龄、性别、平均每日血压和心率参数,所有组具有可比性。各组患者均为中年人,男女人数相等,各组根据平均每日收缩压(SBP)、舒张压(DBP)、脉搏(PBP) BP和心率结果具有可比性。我们发现,与所有其他组相比,第一组夜间收缩压和舒张压下降的百分比明显较低(收缩压为7.6±1.3%,舒张压为10.2±1.4%)。第二组收缩压和舒张压的标准差(分别为19.8±1.1和14.2±0.7)明显高于第一组(分别为16.0±0.9和11.7±0.6)和第三组(分别为16.2±0.7和11.8±0.7)。第一组患者的收缩压和舒张压未下降的频率最高(分别为60%和45%)。在战争期间,高血压患者夜间收缩压和舒张压的下降明显低于战争前、大流行Covid-19和战前和平时期。在这一组中,不吃螃蟹的人也更多。
{"title":"Changes in the normal blood pressure profile under various stress conditions in patients with arterial hypertension","authors":"O. Torbas, Y. Sirenko, S. Progonov","doi":"10.31928/2664-4479-2023.1-2.4047","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.4047","url":null,"abstract":"The aim – to assess the influence of various external factors and stress due to a large-scale military invasion on the daily blood pressure (BP) profile.Materials and methods. This was a retrospective analysis of examined patients who underwent ABPM in the last 5 years. We conditionally divided the observation period into several time intervals: the «War» – 1st group, the «Before the war» – 2nd group, the «Covid» – 3rd group, and the «Peace» – 4th group, in each of it 20 patients were selected by the method of random numbers. All patients underwent ABPM using the Watch BP 03 device (Microlife AG, Switzerland).Results. All groups were comparable according to the age, gender, and average daily BP and heart rate parameters of participants. Patients of all groups were middle-aged, the amount of men and women was equal in all groups, groups were comparable according to the results of average daily systolic (SBP), diastolic (DBP), pulse (PBP) BP and heart rate. We found that the 1st group had a significantly lower percentage of SBP and DBP decrease at night compared to all other groups (7.6±1.3% for SBP and 10.2±1.4% for DBP). The standard deviation of SBP and DBP was significantly higher in the 2nd group (19.8±1.1 and 14.2±0.7, respectively) compared to the 1st group (16.0±0.9 and 11.7±0.6, respectively) and 3rd (16.2±0.7 and 11.8±0.7, respectively). The highest frequency of non-dippers for SBP and DBP was observed in the 1st group (60 and 45 % respectively).Conclusions. During the war, the reduction of SBP and DBP at night in patients with hypertension was significantly lower than in the period before the war, pandemic Covid-19, and peace pre-war. There was also a higher number of non-dippers in this group.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77791588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.7382
G. Solovyan, Т. V. Міkhalieva, L. O. Androsova
A literature review deals with the clinical use of nebivol as a beta-blocker (BB) with vasodilating properties. The principal pharmacological properties and characteristics of the drug, its cardioselectivity and mechanisms of vasodilation are presented. The special place of nebivolol in the treatment of essential arterial hypertension (AH), coronary heart disease (CHD) and heart failure (HF) is outlined. The drug does not possess a diabetogenic activity with a long-term use, and impacts favourably on the parameters of lipid and carbohydrate metabolism. In CHD patients, nebivolol demonstrates the antianginal and antiischemic activities, and reduces the frequency of angina recurrence after coronary artery interventions. The drug is well tolerated and characterized by a high effectiveness with respect to the reduction of mortality rates in patients with chronic HF over 70 years of age, regardless of the left ventricular ejection fraction. Vasodilating BB are preferred in the treatment of CHD patients with type 2 diabetes. In case of non-obstructive coronary lesions, nebivolol is chosen among existing BBs for the treatment of microvascular angina. The use of nebivolol in AH patients, in addition to the antihypertensive effect, is characterized by a favorable impact on the function of endothelium, the metabolic profile, central hemodynamics, health-related quality of life of patients, as well as more favorable profile of side effects
{"title":"Nebivolol as a beta-blocker with vasodilating properties: achievements and prospects","authors":"G. Solovyan, Т. V. Міkhalieva, L. O. Androsova","doi":"10.31928/2664-4479-2023.1-2.7382","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.7382","url":null,"abstract":"A literature review deals with the clinical use of nebivol as a beta-blocker (BB) with vasodilating properties. The principal pharmacological properties and characteristics of the drug, its cardioselectivity and mechanisms of vasodilation are presented. The special place of nebivolol in the treatment of essential arterial hypertension (AH), coronary heart disease (CHD) and heart failure (HF) is outlined. The drug does not possess a diabetogenic activity with a long-term use, and impacts favourably on the parameters of lipid and carbohydrate metabolism. In CHD patients, nebivolol demonstrates the antianginal and antiischemic activities, and reduces the frequency of angina recurrence after coronary artery interventions. The drug is well tolerated and characterized by a high effectiveness with respect to the reduction of mortality rates in patients with chronic HF over 70 years of age, regardless of the left ventricular ejection fraction. Vasodilating BB are preferred in the treatment of CHD patients with type 2 diabetes. In case of non-obstructive coronary lesions, nebivolol is chosen among existing BBs for the treatment of microvascular angina. The use of nebivolol in AH patients, in addition to the antihypertensive effect, is characterized by a favorable impact on the function of endothelium, the metabolic profile, central hemodynamics, health-related quality of life of patients, as well as more favorable profile of side effects","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88886500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.719
V. Tseluyko, R. Askerov
The aim – to analyze the clinical course and prognostic factors in patients with pulmonary embolism (PE) and concomitant atrial fibrillation (AF).Materials and methods. We analyzed 243 medical cards of patients with diagnosis «PE» who were hospitalized to Kharkiv City Clinical Hospital No.8. during 01.01.2018 – 01.01.2020 period. The inclusion criteria was diagnosis «PE» verified by multispiral computed tomography angiography (CTPA) of pulmonary arteries and/or by autopsy. Patients were divided in several groups: 1 – PE with AF (45 pts – 18.5 %), 2 – PE with no AF (198 pts – 81.5 %). Patients from group 1 were divided in such subgroups as: 1А – PE + AF de novo (22 pts – 48.8 %); 1В – PE + AF existing before acute PE (23 pts – 51.2 %). Clinical, anamnestic, biochemical, instrumental parameters, mortality rates were measured; statistical analysis was done.Results and discussion. Pts from group 1 were older (67.2±10.6 vs 58.6±14.6), had more cases of ischemic strokes in past. By admission to hospital most of high-risk patients were among group 1. We noticed that patients from group 1 who had low-risk profile also had respectively higher points measured by PESI. Patients with PE + AF had respectively lower saturation and higher heart rate; granulocyte count and serum creatinine ration. Several parameters measured with CTPA and echocardiography differed significantly in PE + AF and PE without AF groups: diameter pulmonary trunk; diameter of pulmonary arteries, size of the left and right atrium, left ventricle (LV) end diastolic diameter, LV end systolic diameter, LV ejection fraction and mean pulmonary arterial pressure (PAP). There were several differences between 1A and 1B groups: patients with PE + AF existing before had more cases of ischemic stroke. High-risk status was much common among patients with PE + AF de novo despite the fact that all patients with PE + AF with low-risk status had high points and classes measured with PESI. We noticed that patients with PE + AF had also respectively differences in granulocyte count and serum creatinine. There were also differences in echocardiographic parameters as size of left atrium (bigger in group 1B) while mean PAP was much bigger in group 1A. It should be mentioned that general mortality rate was 18.5 %, while there were big differences between mortality rates in groups 2 and 1 (13.6 % vs 44.4 %). Mortality rate differed significantly in patients with PE + AF de novo and PE + AF existing before (67.5 % vs 21.7 %). We used uni- and multivariate analyses to find out prognostic factors (AF is among them).Conclusions. AF was found in 18.5 % of patients with PE, AF de novo – in 9 %. Patients with PE + AF were 8.6 years older than patients with PE without AF. Vein thrombosis is less common among patients with PE + AF. Patients with PE + AF have larger sizes of left and right atrium and more poor ejection fraction of left ventricle. AF, as age, blood saturation, obesity, PESI score, is independent prognost
目的分析肺栓塞(PE)合并心房颤动(AF)患者的临床病程及预后因素。材料和方法。我们分析了哈尔科夫市第八临床医院住院的243例诊断为“PE”的患者的医疗卡。2018年1月1日至2020年1月1日期间。纳入标准是诊断为“PE”,经肺动脉多螺旋ct血管造影(CTPA)和/或尸检证实。患者被分为几组:1 - PE合并房颤(45例- 18.5%),2 - PE合并房颤(198例- 81.5%)。第1组患者分为以下亚组:1А - PE + AF de novo(22例- 48.8%);1В -急性PE前存在PE + AF(23例- 51.2%)。测定临床、记忆、生化、仪器参数、死亡率;进行统计分析。结果和讨论。1组患者年龄较大(67.2±10.6 vs 58.6±14.6),既往缺血性脑卒中病例较多。入院时高危患者以1组居多。我们注意到,1组低风险患者的PESI测量值也分别较高。PE + AF患者分别有较低的饱和度和较高的心率;粒细胞计数和血清肌酐比率。在PE + AF组和PE无AF组,CTPA和超声心动图测量的几个参数有显著差异:肺干直径;肺动脉直径、左右心房大小、左室(LV)舒张末直径、左室收缩末直径、左室射血分数、平均肺动脉压(PAP)。1A组和1B组之间有几个差异:先前存在PE + AF的患者发生缺血性卒中的病例较多。高风险状态在PE + AF新发患者中很常见,尽管事实上所有低风险状态的PE + AF患者都有较高的PESI评分和分级。我们注意到PE + AF患者的粒细胞计数和血清肌酐也分别存在差异。超声心动图参数也有差异,如左心房大小(1B组较大),而平均PAP在1A组大得多。应该提到的是,总死亡率为18.5%,而第2组和第1组的死亡率差异很大(13.6%对44.4%)。新发PE +房颤患者与既往PE +房颤患者的死亡率差异显著(67.5% vs 21.7%)。我们使用单因素和多因素分析来发现预后因素(房颤是其中之一)。肺心病患者中有18.5%发生房颤,9%为新发房颤。PE +房颤患者比PE无房颤患者年龄大8.6岁,PE +房颤患者静脉血栓发生率较低,PE +房颤患者左右心房尺寸较大,左心室射血分数较差。房颤与年龄、血饱和度、肥胖、PESI评分一样,是影响不良临床结局的独立预后因素。Kaplan - Meier AF de novo对PE患者近期预后影响最大。
{"title":"Atrial fibrillation as prognostic factor in patients with pulmonary embolism","authors":"V. Tseluyko, R. Askerov","doi":"10.31928/2664-4479-2023.1-2.719","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.719","url":null,"abstract":"The aim – to analyze the clinical course and prognostic factors in patients with pulmonary embolism (PE) and concomitant atrial fibrillation (AF).Materials and methods. We analyzed 243 medical cards of patients with diagnosis «PE» who were hospitalized to Kharkiv City Clinical Hospital No.8. during 01.01.2018 – 01.01.2020 period. The inclusion criteria was diagnosis «PE» verified by multispiral computed tomography angiography (CTPA) of pulmonary arteries and/or by autopsy. Patients were divided in several groups: 1 – PE with AF (45 pts – 18.5 %), 2 – PE with no AF (198 pts – 81.5 %). Patients from group 1 were divided in such subgroups as: 1А – PE + AF de novo (22 pts – 48.8 %); 1В – PE + AF existing before acute PE (23 pts – 51.2 %). Clinical, anamnestic, biochemical, instrumental parameters, mortality rates were measured; statistical analysis was done.Results and discussion. Pts from group 1 were older (67.2±10.6 vs 58.6±14.6), had more cases of ischemic strokes in past. By admission to hospital most of high-risk patients were among group 1. We noticed that patients from group 1 who had low-risk profile also had respectively higher points measured by PESI. Patients with PE + AF had respectively lower saturation and higher heart rate; granulocyte count and serum creatinine ration. Several parameters measured with CTPA and echocardiography differed significantly in PE + AF and PE without AF groups: diameter pulmonary trunk; diameter of pulmonary arteries, size of the left and right atrium, left ventricle (LV) end diastolic diameter, LV end systolic diameter, LV ejection fraction and mean pulmonary arterial pressure (PAP). There were several differences between 1A and 1B groups: patients with PE + AF existing before had more cases of ischemic stroke. High-risk status was much common among patients with PE + AF de novo despite the fact that all patients with PE + AF with low-risk status had high points and classes measured with PESI. We noticed that patients with PE + AF had also respectively differences in granulocyte count and serum creatinine. There were also differences in echocardiographic parameters as size of left atrium (bigger in group 1B) while mean PAP was much bigger in group 1A. It should be mentioned that general mortality rate was 18.5 %, while there were big differences between mortality rates in groups 2 and 1 (13.6 % vs 44.4 %). Mortality rate differed significantly in patients with PE + AF de novo and PE + AF existing before (67.5 % vs 21.7 %). We used uni- and multivariate analyses to find out prognostic factors (AF is among them).Conclusions. AF was found in 18.5 % of patients with PE, AF de novo – in 9 %. Patients with PE + AF were 8.6 years older than patients with PE without AF. Vein thrombosis is less common among patients with PE + AF. Patients with PE + AF have larger sizes of left and right atrium and more poor ejection fraction of left ventricle. AF, as age, blood saturation, obesity, PESI score, is independent prognost","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78712729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.4856
O. Shumakov, O. Parkhomenko, O. Golubovska
The aim – to determine a prognostically significant set of anamnestic (primarily cardiovascular) risk factors and indicators of the initial clinical condition in the population of patients with COVID-19, on the basis of which to develop a scale for assessing the clinical condition to identify patients with a more severe subsequent course of the disease for the individualization of treatment tactics.Materials and methods. The retrospective analysis included data on 104 patients with COVID-19 (50 men and 54 women, aged 24 to 84 years), who during 2020-2021 underwent treatment (16 days) in clinics of Ukraine within the framework of the program for studying the effectiveness of treatment COVID-19. Risk factors (advanced age, inflammatory diseases, hypertension, obesity, diabetes, coronary heart disease, heart failure (HF)), dynamics of the clinical state (heart rate, body temperature, blood pressure, SpO2, respiratory rate (RR), clinical symptoms and signs from all systems of the body) were assessed. Based on the dynamics of the clinical condition (according to a specially developed scale), all patients were divided into subgroup A (66 patients, more severe hospital course of COVID-19, ≥ 7 points) and subgroup B (38 patients, milder course of COVID-19, < 7) points).Results and discussion. Among the anamnestic risk factors (RF) of a more severe hospitalization for COVID-19, the following were more informative than others: age > 53 years (HR 1.8 (1.11–3.02)), history of coronary artery disease (HR 1.42 (1.09–1.85)) and SN (HR 1.67 (1.41–1.96)), as well as a model built taking into account all the estimated RFs according to their significance (HR = 1.88 (1.37–2.74), area under the ROC curve (ROC) 0.73). Among the clinical markers (CM) of the first day, the most informative were: RR > 20/min (HR 1.74 (1.10–2.74)), body temperature > 37.8 °C (HR 1.48 (1.13–1.94)) and a model with eight KM (HR 2.45 (1.55–3.87), ROC 0.80). The obtained scales were additive: the combined scale of RF and CM had ROC 0.84, value > 21 units on the first day of COVID-19 had a sensitivity of 76 % and a specificity of 76 % (HR 2.38 (1.58–3.58)) in predicting the adverse course of the disease during the next 16 days.Conclusions. The risk assessment system developed by us, based on clinical and anamnestic data, on the first day of treatment for COVID-19 allows predicting a more severe course of the disease. The data obtained by us require further study in a prospective study.
{"title":"Development of an innovative technology for predicting the course of COVID-19 based on the analysis of clinical and anamnestic data","authors":"O. Shumakov, O. Parkhomenko, O. Golubovska","doi":"10.31928/2664-4479-2023.1-2.4856","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.4856","url":null,"abstract":"The aim – to determine a prognostically significant set of anamnestic (primarily cardiovascular) risk factors and indicators of the initial clinical condition in the population of patients with COVID-19, on the basis of which to develop a scale for assessing the clinical condition to identify patients with a more severe subsequent course of the disease for the individualization of treatment tactics.Materials and methods. The retrospective analysis included data on 104 patients with COVID-19 (50 men and 54 women, aged 24 to 84 years), who during 2020-2021 underwent treatment (16 days) in clinics of Ukraine within the framework of the program for studying the effectiveness of treatment COVID-19. Risk factors (advanced age, inflammatory diseases, hypertension, obesity, diabetes, coronary heart disease, heart failure (HF)), dynamics of the clinical state (heart rate, body temperature, blood pressure, SpO2, respiratory rate (RR), clinical symptoms and signs from all systems of the body) were assessed. Based on the dynamics of the clinical condition (according to a specially developed scale), all patients were divided into subgroup A (66 patients, more severe hospital course of COVID-19, ≥ 7 points) and subgroup B (38 patients, milder course of COVID-19, < 7) points).Results and discussion. Among the anamnestic risk factors (RF) of a more severe hospitalization for COVID-19, the following were more informative than others: age > 53 years (HR 1.8 (1.11–3.02)), history of coronary artery disease (HR 1.42 (1.09–1.85)) and SN (HR 1.67 (1.41–1.96)), as well as a model built taking into account all the estimated RFs according to their significance (HR = 1.88 (1.37–2.74), area under the ROC curve (ROC) 0.73). Among the clinical markers (CM) of the first day, the most informative were: RR > 20/min (HR 1.74 (1.10–2.74)), body temperature > 37.8 °C (HR 1.48 (1.13–1.94)) and a model with eight KM (HR 2.45 (1.55–3.87), ROC 0.80). The obtained scales were additive: the combined scale of RF and CM had ROC 0.84, value > 21 units on the first day of COVID-19 had a sensitivity of 76 % and a specificity of 76 % (HR 2.38 (1.58–3.58)) in predicting the adverse course of the disease during the next 16 days.Conclusions. The risk assessment system developed by us, based on clinical and anamnestic data, on the first day of treatment for COVID-19 allows predicting a more severe course of the disease. The data obtained by us require further study in a prospective study.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86405008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.3039
O. Rekovets, Y. Sirenko
The aim – to identify patients with true resistant arterial hypertension and to assess patients’ adherence to treatment on the background of a fixed combination of antihypertensive drugs.Materials and methods. 1146 patients with resistant hypertension were included in the study. Men and women over the age of 18 were included, provided that the average level of office blood pressure (BP) was greater than 140/90 mm Hg, when taking 3 or more antihypertensive drugs. Morisky – Green Questionnaire (in a modified scale) (MMAS-8) on patient adherence to treatment. To determine adherence to treatment in some patients, determination of drugs in urine was carried out in the central laboratory. All patients were initially subjected to the following tests: measurement of office SBP, DBP and heart rate, daily monitoring of BP, biochemical blood test.Results and discussion. 51.4 % of patients took 3 antihypertensive drugs. 48.6 % took 4-6 antihypertensive drugs: among them, 4 drugs – 37.1 %, 9.1 % – took 5 drugs, and 2.4 % – 6 drugs. The degree of decrease in office BP among patients taking 3 or more antihypertensive drugs was 43.47 ± 0.65 mm Hg for systolic BP, and 20.33 ± 0.74 mm Hg for diastolic BP (p<0.001 for both values). 355 (31 %) patients failed to achieve the target level of office BP. They had true resistant hypertension. According to the Morisky – Green adherence questionnaire, on the background of the fixed triple combination of valsartan/amlodipine/hydrochlorothiazide, there was a significant improvement in adherence for all questions of the questionnaire. Patients began to forget to take pills significantly less, therapy became stable and regular, there were much fewer cases of stopping taking drugs due to deterioration of the patient’s condition after taking them, all 100 % of patients took antihypertensive drugs on the eve of the visit to the doctor, patients stopped canceling therapy due to their well-being at against the background of treatment, much fewer patients were bothered by the inconvenient regimen of taking drugs. Patient pill size was significant in only 11.4 % of patients at baseline and did not significantly change after 3 months of treatment with the fixed triple combination. But if patients had a choice, 60 % of them would choose the smaller pill. According to the determination of drugs in urine among 12 patients, we found that 25 % of patients (n=3) did not take drugs at all.Conclusions. Resistant arterial hypertension was found in 31 % of patients taking 3 or more antihypertensive drugs. When determining adherence to treatment based on the detection of drugs in urine, 25 % of patients with resistant arterial hypertension did not take the prescribed drugs at all, that is, they had pseudoresistance.
目的是识别真正的顽固性动脉高血压患者,并在固定的抗高血压药物组合的背景下评估患者对治疗的依从性。材料和方法。1146例顽固性高血压患者纳入研究。年龄在18岁以上的男性和女性,只要在服用3种或3种以上的降压药时,平均办公室血压(BP)水平大于140/90 mm Hg。Morisky - Green问卷(改良量表)(MMAS-8)关于患者对治疗的依从性。为了确定一些患者的治疗依从性,在中心实验室进行了尿中药物的测定。所有患者最初接受以下检查:办公室收缩压、舒张压和心率测量,每日血压监测,血液生化检查。结果和讨论。51.4%的患者同时服用3种降压药。服用4 ~ 6种降压药的占48.6%,其中服用4种降压药的占37.1%,服用5种降压药的占9.1%,服用6种降压药的占2.4%。服用3种及以上降压药患者的办公室血压下降程度分别为收缩压43.47±0.65 mm Hg和舒张压20.33±0.74 mm Hg (p<0.001)。355例(31%)患者未达到办公室血压目标水平。他们有真正的顽固性高血压。Morisky - Green依从性问卷显示,在缬沙坦/氨氯地平/氢氯噻嗪固定三联用药的背景下,问卷所有问题的依从性均有显著提高。患者遗忘服药的情况明显减少,治疗变得稳定和规律,服药后因病情恶化而停药的情况明显减少,100%的患者在就诊前夕服用降压药,患者在治疗的背景下因健康原因停止取消治疗,很少有患者因服药方案不方便而烦恼。患者药片大小在基线时只有11.4%的患者具有显著性,并且在使用固定三联疗法治疗3个月后没有显着变化。但如果病人可以选择,60%的人会选择较小的药片。通过对12例患者尿液中药物的检测,我们发现25%的患者(n=3)根本没有服用药物。在服用3种及以上降压药的患者中,有31%出现了顽固性动脉高血压。在根据尿中药物检测确定治疗依从性时,25%的顽固性动脉高血压患者根本没有服用处方药物,即存在假耐药。
{"title":"Adherence to treatment in patients with resistant arterial hypertension","authors":"O. Rekovets, Y. Sirenko","doi":"10.31928/2664-4479-2023.1-2.3039","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.3039","url":null,"abstract":"The aim – to identify patients with true resistant arterial hypertension and to assess patients’ adherence to treatment on the background of a fixed combination of antihypertensive drugs.Materials and methods. 1146 patients with resistant hypertension were included in the study. Men and women over the age of 18 were included, provided that the average level of office blood pressure (BP) was greater than 140/90 mm Hg, when taking 3 or more antihypertensive drugs. Morisky – Green Questionnaire (in a modified scale) (MMAS-8) on patient adherence to treatment. To determine adherence to treatment in some patients, determination of drugs in urine was carried out in the central laboratory. All patients were initially subjected to the following tests: measurement of office SBP, DBP and heart rate, daily monitoring of BP, biochemical blood test.Results and discussion. 51.4 % of patients took 3 antihypertensive drugs. 48.6 % took 4-6 antihypertensive drugs: among them, 4 drugs – 37.1 %, 9.1 % – took 5 drugs, and 2.4 % – 6 drugs. The degree of decrease in office BP among patients taking 3 or more antihypertensive drugs was 43.47 ± 0.65 mm Hg for systolic BP, and 20.33 ± 0.74 mm Hg for diastolic BP (p<0.001 for both values). 355 (31 %) patients failed to achieve the target level of office BP. They had true resistant hypertension. According to the Morisky – Green adherence questionnaire, on the background of the fixed triple combination of valsartan/amlodipine/hydrochlorothiazide, there was a significant improvement in adherence for all questions of the questionnaire. Patients began to forget to take pills significantly less, therapy became stable and regular, there were much fewer cases of stopping taking drugs due to deterioration of the patient’s condition after taking them, all 100 % of patients took antihypertensive drugs on the eve of the visit to the doctor, patients stopped canceling therapy due to their well-being at against the background of treatment, much fewer patients were bothered by the inconvenient regimen of taking drugs. Patient pill size was significant in only 11.4 % of patients at baseline and did not significantly change after 3 months of treatment with the fixed triple combination. But if patients had a choice, 60 % of them would choose the smaller pill. According to the determination of drugs in urine among 12 patients, we found that 25 % of patients (n=3) did not take drugs at all.Conclusions. Resistant arterial hypertension was found in 31 % of patients taking 3 or more antihypertensive drugs. When determining adherence to treatment based on the detection of drugs in urine, 25 % of patients with resistant arterial hypertension did not take the prescribed drugs at all, that is, they had pseudoresistance.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"71 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90685587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.5766
Ya.Yu. Dzhun, G. Mankovsky
The aim – assessment of the diagnostic and prognostic value of glycemic variability indicators in patients with coronary artery disease (CAD) after percutaneous coronary intervention followed by optimal drug therapy.Materials and methods. 121 patients with impaired glucose metabolism took part in the study, who, depending on the presence of CAD, were divided into two groups: group I (n=65) – CAD (+), group II (n=56) – CAD (-). Glucose variability was determined using a continuous glucose monitoring system for 6 days before the start of the study. The method of choice for coronary artery revascularization was percutaneous coronary intervention followed by optimal drug therapy. The results of the study were evaluated by the presence of clinical manifestations of the progression of coronary heart disease and the development of acute cardiovascular events in patients.Results and discussion. Distribution of patients by gender, bad habits and most concomitant diseases, both groups were comparable, the average age of patients was 54.2 years. With comparable initial values of glycated hemoglobin (7.3±0.9 % vs 7.5±1.2 %, p=0.29), the indicators of glycemia variability were significantly higher in patients with coronary artery disease (mean glucose 8.6±2.1 vs 7.5±1.9 mmol/L; p<0.05). During the observation period (2 years), 20 patients (16.5 %), of which 17 (14.1 %) had a history of CHD and 3 (2.5 %) without a previous diagnosis of CHD, had clinical signs of progression of this disease. 7 (5.8 %) patients developed an acute coronary syndrome, among which 3 (2.5 %) had unstable angina, 3 (2.5 %) had an acute non-Q myocardial infarction, and 1 (0.8 %) had an acute Q-myocardial infarction. When comparing the frequency of development and assessing the relative risk of progression of clinical symptoms of CAD and the development of acute cardiovascular events, the most significant factors were the percentage of time below the target range of glycemia < 3.9 mmol/l more than 5 % per day and SD above 2.Conclusion. Increased glycemic variability (SD > 2 mmol/L) and period of hypoglycemia < 3.9 mmol/L more than 3 % per day are negatively associated with clinical progression of CAD and the development of recurrent acute cardiovascular events in middle-aged patients with concomitant diabetes mellitus after percutaneous coronary intervention followed by optimal drug therapy.
目的评价经皮冠状动脉介入治疗后最佳药物治疗对冠心病(CAD)患者血糖变异性指标的诊断和预后价值。材料和方法。121例糖代谢受损患者参与研究,根据是否存在CAD,将其分为两组:I组(n=65) - CAD (+), II组(n=56) - CAD(-)。在研究开始前6天使用连续血糖监测系统测定血糖变异性。冠状动脉血管重建术的选择方法是经皮冠状动脉介入治疗,然后进行最佳药物治疗。研究结果是通过冠心病进展的临床表现和患者急性心血管事件的发展来评估的。结果和讨论。患者的分布按性别、不良生活习惯及最伴发疾病分,两组具有可比性,患者平均年龄为54.2岁。糖化血红蛋白初始值比较(7.3±0.9% vs 7.5±1.2%,p=0.29),冠状动脉疾病患者的血糖变异性指标明显更高(平均血糖8.6±2.1 vs 7.5±1.9 mmol/L;p 2 mmol/L)、低血糖期< 3.9 mmol/L > 3% /天与经皮冠状动脉介入治疗后中年合并糖尿病患者冠心病临床进展及急性心血管事件复发呈负相关。
{"title":"Diagnostic and prognostic value of glycemic variability in patients with obstructive coronary artery disease after percutaneous coronary intervention","authors":"Ya.Yu. Dzhun, G. Mankovsky","doi":"10.31928/2664-4479-2023.1-2.5766","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.5766","url":null,"abstract":"The aim – assessment of the diagnostic and prognostic value of glycemic variability indicators in patients with coronary artery disease (CAD) after percutaneous coronary intervention followed by optimal drug therapy.Materials and methods. 121 patients with impaired glucose metabolism took part in the study, who, depending on the presence of CAD, were divided into two groups: group I (n=65) – CAD (+), group II (n=56) – CAD (-). Glucose variability was determined using a continuous glucose monitoring system for 6 days before the start of the study. The method of choice for coronary artery revascularization was percutaneous coronary intervention followed by optimal drug therapy. The results of the study were evaluated by the presence of clinical manifestations of the progression of coronary heart disease and the development of acute cardiovascular events in patients.Results and discussion. Distribution of patients by gender, bad habits and most concomitant diseases, both groups were comparable, the average age of patients was 54.2 years. With comparable initial values of glycated hemoglobin (7.3±0.9 % vs 7.5±1.2 %, p=0.29), the indicators of glycemia variability were significantly higher in patients with coronary artery disease (mean glucose 8.6±2.1 vs 7.5±1.9 mmol/L; p<0.05). During the observation period (2 years), 20 patients (16.5 %), of which 17 (14.1 %) had a history of CHD and 3 (2.5 %) without a previous diagnosis of CHD, had clinical signs of progression of this disease. 7 (5.8 %) patients developed an acute coronary syndrome, among which 3 (2.5 %) had unstable angina, 3 (2.5 %) had an acute non-Q myocardial infarction, and 1 (0.8 %) had an acute Q-myocardial infarction. When comparing the frequency of development and assessing the relative risk of progression of clinical symptoms of CAD and the development of acute cardiovascular events, the most significant factors were the percentage of time below the target range of glycemia < 3.9 mmol/l more than 5 % per day and SD above 2.Conclusion. Increased glycemic variability (SD > 2 mmol/L) and period of hypoglycemia < 3.9 mmol/L more than 3 % per day are negatively associated with clinical progression of CAD and the development of recurrent acute cardiovascular events in middle-aged patients with concomitant diabetes mellitus after percutaneous coronary intervention followed by optimal drug therapy.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90755195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-05-03DOI: 10.31928/2664-4479-2023.1-2.2029
M. Kopytsya, Y. Hilova, I. M. Kutya, Y. Rodionova, L. L. Petieniova
The aim – to study the relationship between the sST2 level and the degree of epicardial blood flow recovery and with the heart failure (HF) development in 6 month follow-up in patients with STEMI after PCI.Materials and methods. The study involved 61 patients with STEMI – 51 (83.6 %) males and 10 (16.4 %) females, with average age of 59.85±10.01 years. Standard clinical and biochemical parameters were determined, as well as sST2 level was measured by enzyme immunoassay using a reagent kit «Presage ST2 analysis, Critical Diagnosis» (USA) in all patients, on the first day of the disease. Patients were divided into two groups depending on the degree of blood flow recovery in a culprit artery (TIMI) The first group (n=12) included patients with TIMI 0, I, II, the second group (n=49) with TIMI III.Results and discussion. The sST2 level was significantly higher in the first hours of the disease in the group with unrepaired or decreased epicardial blood flow (TIMI 0–II) after PCI (p=0.003). ROC analysis showed that sST2 levels above 34.2 ng/ml, detected in the first hours of the disease, is an independent marker of adverse revascularization (TIMI 0–I) in patients with STEMI with a sensitivity of 92.3 % and a specificity of 62.5 %; the area under curve (the AUC) is 0.8 (95 % CI=0.651–0.873; p=0.001). When conducting a univariate (χ2=17.741; p=0.04) and multivariate (χ2=9.293; p=0.004) logistic analyzes, sST2 was a significant influencer of the unfavorable outcome of epicardial vascular revascularization (TIMI 0–ІІ).Conclusions. sST2 is highly associated with the degree of epicardial blood flow recovery in patients with STEMI and is of great clinical importance as diagnostic marker.
{"title":"Soluble ST2 association with outcome of revascularization and the heart failure development in patients with acute myocardial infarction with ST segment elevation","authors":"M. Kopytsya, Y. Hilova, I. M. Kutya, Y. Rodionova, L. L. Petieniova","doi":"10.31928/2664-4479-2023.1-2.2029","DOIUrl":"https://doi.org/10.31928/2664-4479-2023.1-2.2029","url":null,"abstract":"The aim – to study the relationship between the sST2 level and the degree of epicardial blood flow recovery and with the heart failure (HF) development in 6 month follow-up in patients with STEMI after PCI.Materials and methods. The study involved 61 patients with STEMI – 51 (83.6 %) males and 10 (16.4 %) females, with average age of 59.85±10.01 years. Standard clinical and biochemical parameters were determined, as well as sST2 level was measured by enzyme immunoassay using a reagent kit «Presage ST2 analysis, Critical Diagnosis» (USA) in all patients, on the first day of the disease. Patients were divided into two groups depending on the degree of blood flow recovery in a culprit artery (TIMI) The first group (n=12) included patients with TIMI 0, I, II, the second group (n=49) with TIMI III.Results and discussion. The sST2 level was significantly higher in the first hours of the disease in the group with unrepaired or decreased epicardial blood flow (TIMI 0–II) after PCI (p=0.003). ROC analysis showed that sST2 levels above 34.2 ng/ml, detected in the first hours of the disease, is an independent marker of adverse revascularization (TIMI 0–I) in patients with STEMI with a sensitivity of 92.3 % and a specificity of 62.5 %; the area under curve (the AUC) is 0.8 (95 % CI=0.651–0.873; p=0.001). When conducting a univariate (χ2=17.741; p=0.04) and multivariate (χ2=9.293; p=0.004) logistic analyzes, sST2 was a significant influencer of the unfavorable outcome of epicardial vascular revascularization (TIMI 0–ІІ).Conclusions. sST2 is highly associated with the degree of epicardial blood flow recovery in patients with STEMI and is of great clinical importance as diagnostic marker.","PeriodicalId":23419,"journal":{"name":"Ukrainian Journal of Cardiology","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85176233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}